Can You Take a GLP-1 With Tamoxifen? (October 2026)

01 · The honest answer

Can you take a GLP-1 with tamoxifen?

Do not assume the combination is safe or unsafe: ask your oncologist and prescriber.

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine. In the UK it is licensed for weight management in adults and for type 2 diabetes.¹ It activates two natural gut-hormone receptors, GIP and GLP-1, which help regulate appetite, slow how quickly the stomach empties and improve the way the body responds to insulin.¹ The patient leaflet and prescribing information are where interactions with other medicines are listed, so take them to your oncology team.¹³

02 · What to do next

The decision you are actually facing

For most readers the real question is whether to raise weight management with their cancer team at all. We think you should, before ordering anything. Your oncologist knows your diagnosis, your treatment plan and the rest of your medicines. A weight-loss prescriber can only see what you tell them. Putting both in the same conversation is the safest route, and it is rarely a long one.

Go in prepared. Bring the name of the medicine you are considering, and tell them whether you want to use it for weight management. Bring the official leaflet. Ask whether they are happy for you to start, whether they want you to wait, and what they would like to monitor. If your oncologist says no, that is a complete answer for now. You can revisit it later when your treatment changes.

If your oncology team is comfortable, a consultation can follow. Our prescribers review every order, and you should disclose your tamoxifen and your cancer history in full. The medicine is prescription-only and supplied only after an online consultation reviewed by a GPhC-registered prescriber. It is used alongside a reduced-calorie diet and increased physical activity, and individual results vary.¹ When you are ready, see the Mounjaro consultation page, or our wider weight loss clinic overview. For a closer look at one medicine, read our guide to Mounjaro and tamoxifen.

Related guide: mounjaro with tamoxifen.

03 · What the evidence gap means

Why you should not rely on a general answer

The question has to be answered by someone with access to your whole clinical picture.

You may see a claim online that there is no interaction between the two. Treat that kind of statement with caution. A confident general claim is not the same as advice made for your situation.

The Summary of Product Characteristics is the legal document describing how a medicine should be used, including what to be careful about when combining it with others.¹ The patient leaflet translates this into plain language and tells you to inform your doctor or pharmacist about all the medicines you take.¹³

If a page tells you that nothing could possibly go wrong, you may feel less inclined to mention your cancer treatment in a weight-loss consultation. Tell every clinician about everything you take, including tamoxifen, other prescription medicines, over-the-counter products and anything you buy as a supplement.

If you want a related, medicine-specific read, our page on taking Mounjaro while on tamoxifen follows the same principle: a clear route to the right professional.

04 · Talking to your oncologist

How to raise this with your oncologist

Start by saying plainly that you are thinking about a weight-management medicine and want their view. Your oncologist or breast care nurse hears questions like this and would rather know than find out later. Make the request specific, because a vague question gets a vague answer.

Useful questions to take with you: Is there any reason my cancer treatment plan makes a GLP-1 medicine unsuitable for me? Should I wait until a particular point in my treatment? Is there anything you want monitored if I start? Who should I contact if I develop a new symptom? Should my weight-loss prescriber write to you, or should I pass on what they decide?

Bring the leaflet. The patient information for Mounjaro sets out how the medicine is used and what to tell your doctor.¹³ Bring the prescribing information too, which is publicly available.¹ Your clinician can read the interaction sections themselves, which is more reliable than a summary from us.

Say why you want to lose weight. Weight change is a common worry during hormone therapy, and your team may have their own approaches, support services or dietitian referrals. Those may be worth using alongside, or instead of, a medicine. They may also have advice about timing that we cannot see from outside your care.

Write down the answer. If your oncologist agrees, note the conditions they set. If they decline, ask whether that is permanent or just for now. Either way, keep a record. When you later complete a consultation with any prescriber, you can state exactly what your cancer team said.

Finally, be honest about your goals. If you are hoping for dramatic results, your team can help set realistic expectations. Treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them, and results vary from person to person. Our page on tamoxifen and weight loss drugs goes further into how to frame that conversation.

05 · How Mounjaro works

How a GLP-1 and GIP medicine works

Mounjaro contains tirzepatide, which activates two natural gut-hormone receptors at once: GIP and GLP-1.¹ Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin. In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹

This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide, sold as Wegovy and Ozempic.¹

Why does the mechanism matter when you take other medicines? Because one of the actions is a slower emptying of the stomach. Ask your pharmacist or prescriber whether any of your tablets need special timing. Let them make that judgement with your full medicine list in front of them.

It also matters because the medicine acts on appetite and digestion, so early changes are often felt in the stomach and gut. Your prescriber will talk you through side effects, and the patient leaflet lists them.¹³ If you are already managing symptoms from cancer treatment, tell the prescriber, so that new gut symptoms can be interpreted properly instead of being blamed on the wrong thing.

Finally, the medicine is a prescription treatment, not a supplement and not a lifestyle shortcut. It is licensed for adults, supplied in a pre-filled multi-dose pen called a KwikPen, and dosed once weekly across six strengths from 2.5mg to 15mg.¹ A prescriber chooses the starting dose and any step-ups with you, with your oncology plan in mind.

06 · What trials show

What the weight-loss trials show

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.²

The trial result is general, and it comes from a broad adult population.

For a worked example of what the averages mean in practice, someone starting at 100 kg who matched the 15mg average would lose about 21 kg. That is straight arithmetic on the trial average, not a forecast, and not a promise. Many people lose less, and some lose more.

Equally, trial participants were followed on a structured programme. Real life includes holidays, illness, appointments and treatment side effects. If you are managing cancer treatment, your energy, appetite and activity may fluctuate, and that may affect how you respond to any weight-management approach.

Ask yourself what you actually want from treatment: a lower weight for health reasons, easier movement, or relief from appetite changes. Share that with your team, who can judge whether a medicine, a dietitian, a physiotherapist or a combination is a better fit.

07 · NHS and private routes

NHS and private routes to treatment

Mounjaro is available on the NHS, but access is being phased in over several years.⁴ NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first, initially BMI 40+ with four or more qualifying conditions.⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

If you are under hospital or specialist care for breast cancer, the NHS route has an extra advantage: your own clinicians are already involved. Ask your GP or breast care team whether you might be eligible for NHS weight-management support, and what the local pathway looks like. The NHS guide to the medicine explains who it is for.⁵

Private treatment is quicker to start, and it works through a different structure. You complete a free online consultation, a GPhC-registered prescriber reviews it, and the pharmacy dispenses if you are suitable. The key difference for you is communication. A private prescriber will not automatically know your oncology plan unless you tell them, so take responsibility for passing on what your cancer team has said.

Think of private care as an addition to your existing team, never a substitute. A prescriber who knows you take tamoxifen can decline, ask for more information, or ask you to speak to your oncologist first. That is a safeguard, not an obstacle, and if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

If you are considering private treatment, you can start with our Mounjaro consultation page.

08 · Safety and reporting

Side effects, safety and reporting

Any new symptom while you are on a GLP-1 medicine and a cancer treatment should be reported to a clinician, not self-diagnosed. Like all medicines, Mounjaro can cause side effects, and most are digestive: the most common, affecting more than 1 in 10 people, are nausea, diarrhoea, vomiting, constipation and abdominal discomfort. Read the patient leaflet before you start, and read it again if something changes.

Tamoxifen has its own side effects, and some may overlap with the symptoms people notice when starting a weight-management injection, such as changes in appetite or in how you feel day to day. That overlap is a reason to be systematic. Keep a simple note of when you started each medicine, when you changed a dose and when any symptom began. It helps your clinicians work out what is responsible.

Report suspected side effects through the MHRA Yellow Card scheme, which accepts reports from patients as well as professionals.¹⁹ A report adds to the safety picture for everyone.

Be wary of anyone offering to supply a GLP-1 medicine without a consultation or prescription. The MHRA publishes counterfeit medicine alerts, and fake pens are a recognised risk.⁷ A person with a cancer diagnosis has even more reason to use only a regulated pharmacy. You can check our registration, GPhC 9012878, on the public register.

Finally, never make changes to tamoxifen because of a weight-loss medicine. Do not skip, delay or stop it without your oncology team's instruction. If a weight-loss prescriber suggests something that touches your cancer treatment, pause and take it back to your oncologist.

09 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

10 · Stopping, storage and ordering

Storage, stopping and ordering practicalities

If you and your clinicians decide to go ahead, a few practical facts help. Store pens in the fridge until first use. Once in use, a KwikPen can be kept out of the fridge at a temperature not above 30°C for up to 30 days after first use, and must then be thrown away.¹³ Unopened pens keep until the printed expiry date when stored at 2–8°C. Follow the pen's instructions for the injection itself.

Stopping is also worth understanding in advance, because your cancer treatment may change. Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system.¹ There is no way to speed this up, and nothing needs doing while it clears. If your oncologist asks you to pause, tell your prescriber straight away. Our guide on whether you can take a GLP-1 temporarily covers stopping and restarting in more detail.

If you order from us, the process has four steps. First, a free online consultation, which is a short health questionnaire with no charge and no obligation. Second, a review by a GPhC-registered prescriber, not a scoring script. Third, dispensing by our registered pharmacy, with same-day dispatch when ordered by 3pm. Fourth, free next-day tracked delivery in temperature-controlled packaging.

Our supply comes direct from Eli Lilly's UK distribution through LillyDirect, with genuine KwikPens. Needles, a sharps bin and injection guidance are included with every order. Aftercare includes ongoing monthly reviews, dose titration and follow-up assessments by the prescribing team. Repeat orders re-check suitability, and nothing ships automatically.

Support is available Monday to Friday, 9am to 5pm, at support@everydaymeds.co.uk.